Cash Flow Statement

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Asset Utilization Ratio Assets Average EBIT Margin EBITDA Margin EBT Margin Enterprise Value Equity Average Equity Ratio FCF Margin Invested Capital Net Margin Operating Margin Return on Assets Return on Equity Return on Sales

Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to 303.42%.